tramp c2 murine pca cells  (ATCC)

Journal: Clinical and Translational Medicine

Article Title: Reduction of myeloid‐derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment

doi: 10.1002/ctm2.70048

Figure Lengend Snippet: A Full circle translational research design to explore the immunoregulatory effects of WBM in PCa patients. The initial single‐arm Phase I clinical trial involving WBM tablet consumption (NCT00779168) in PCa patients identified circulating MDSCs as immune cells responsive to WBM treatment. Building upon these findings, the current study includes experiments on PCa murine models and analysis of PCa patients in a dual‐centre, two‐arm, open‐label, randomised Phase II trial (NCT04519879). This bidirectional translational research approach has supported the immunomodulatory role of WBM on MDSCs, thus strengthening the rationale for using WBM as a nutraceutical approach to slow the progression of prostate cancer.

Article Snippet: Murine PCa cell lines (TRAMP‐C2 and MyC‐CaP) were purchased from the American Type Culture Collection (ATCC) and were cultured in Dulbecco's modified Eagle's medium (DMEM) with 4 mM L‐glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, .005 mg/mL bovine insulin, 10 nM dehydroisoandrosterone, 5% Nu‐Serum IV, 5% fetal bovine serum (FBS), 1% penicillin and 100 μg/mL streptomycin.

Techniques: Clinical Proteomics